Average Co-Inventor Count = 2.09
ph-index = 7
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Jenrin Discovery, Inc. (27 from 27 patents)
2. Other (1 from 832,680 patents)
3. Bristol-myers Squibb Pharma Company (1 from 234 patents)
4. Dupont Pharmaceuticals Company (1 from 106 patents)
5. Wisys Technology Foundation, Inc. (1 from 99 patents)
6. Jensen Discovery, Inc. (1 from 1 patent)
7. Jenrm Discovery, Inc. (1 from 1 patent)
33 patents:
1. 11179370 - Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
2. 10617673 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
3. 9987253 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
4. 9517228 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
5. 9133127 - Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
6. 8853252 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
7. 8716265 - 4-quinolinemethanols as anti-malarial agents
8. 8680131 - Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
9. 8648072 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
10. 8580768 - Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
11. 8541475 - MAO-B inhibitors useful for treating obesity
12. 8334282 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
13. 8252791 - Purine compounds as cannabinoid receptor blockers
14. 8236821 - Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity
15. 8217038 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes